Moderna Inc (MRNA)vsNuvectis Pharma Inc (NVCT)
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
NVCT
Nuvectis Pharma Inc
$23.00
+4.64%
HEALTHCARE · Cap: $713.93M
Smart Verdict
WallStSmart Research — data-driven comparison
NVCT leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NVCT
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Intrinsic value data unavailable for NVCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NVCT
NVCT has a balanced fundamental profile.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NVCT
The primary concerns for NVCT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NVCT is a value play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NVCT generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nuvectis Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. The company is headquartered in Fort Lee, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?